Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study by Lindemann, K et al.
Body mass, diabetes and smoking, and endometrial cancer risk:
a follow-up study
K Lindemann*,1, LJ Vatten
2,3, M Ellstrøm-Engh
1 and A Eskild
1,4
1Department of Obstetrics and Gynaecology, Medical Faculty, Division of Akershus University Hospital, 1478 Lørenskog, Norway;
2Department of Public
Health, Faculty of Medicine, Norwegian University of Science and Technology, 7289 Trondheim, Norway;
3International Agency for Research on Cancer,
69372 Lyon, France;
4Division of Mental Health, Norwegian Institute of Public Health, PO Box 4404 Nydalen, 0403 Oslo, Norway
We examined the relationship of body mass index (BMI), diabetes and smoking to endometrial cancer risk in a cohort of 36 761
Norwegian women during 15.7 years of follow-up. In multivariable analyses of 222 incident cases of endometrial cancer, identified by
linkage to the Norwegian Cancer Registry, there was a strong increase in risk with increasing BMI (P-trend o0.001). Compared to
the reference (BMI 20–24kgm
 2), the adjusted relative risk (RR) was 0.53 (95% confidence interval (CI): 0.19–1.47) for
BMIo20kgm
 2, 4.28 (95% CI: 2.58–7.09) for BMI of 35–39kgm
 2 and 6.36 (95% CI: 3.08–13.16) for BMIX40kgm
 2. Women
with known diabetes at baseline were at three-fold higher risk (RR 3.13, 95% CI: 1.92–5.11) than those without diabetes; women
who reported current smoking at baseline were at reduced risk compared to never smokers (RR 0.55, 95% CI: 0.35–0.86). The
strong linear positive association of BMI with endometrial cancer risk and a strongly increased risk among women with diabetes
suggest that any increase in body mass in the female population will increase endometrial cancer incidence.
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Endometrial cancer is the most commonly diagnosed cancer of the
female genital tract in developed countries (Parker et al, 1997). The
increasing incidence is partly due to increased life expectancy, but
changes in lifestyle factors are also likely to be important.
Previous studies have shown high body mass index (BMI) to be
associated with increased risk of endometrial cancer (Tretli and
Magnus, 1990; Swanson et al, 1993; Ballard-Barbash and Swanson,
1996; Goodman et al, 1997; Furberg and Thune, 2003; Jonsson
et al, 2003; Schouten et al, 2006; Bjorge et al, 2007), and obesity has
been estimated to account for about 40% of endometrial cancer
incidence in affluent societies (Bergstrom et al, 2001). However, it
is still not clear whether the effect of obesity on risk displays a
linear relation, or if there is a threshold effect leading to higher risk
only among obese women (BMIX30kgm
 2) (IARC, 2002).
Few studies have investigated a possible differential effect of
BMI on endometrial cancer risk before and after menopause
(La Vecchia et al, 1991; Tornberg and Carstensen, 1994). These
studies tended to show a possible threshold effect in premeno-
pausal women, whereas in older women there appears to be a
linear increase with BMI. Diabetes has also been related to
increased endometrial cancer risk (Goodman et al, 1997;
Weiderpass et al, 1997; Shoff and Newcomb, 1998; Friberg et al,
2007), whereas several studies have shown a negative association
with smoking (Austin et al, 1993; Brinton et al, 1993; Weiderpass
and Baron, 2001; Viswanathan et al, 2005). These effects have been
related to plasma concentrations of endogenous hormones, insulin
and other growth factors.
The marked effect of obesity on endometrial cancer risk and the
increasing body weight in many populations indicate that the
incidence of this disease will continue to increase. To investigate
this issue further, we have studied endometrial cancer risk in a
prospective study of 36761 women in relation to increments of
BMI, diabetes and smoking in all women and separately in women
younger than or older than 55 years of age.
MATERIALS AND METHODS
During 1984–1986, a health survey was conducted among men and
women aged X20 years in Nord-Trøndelag county in Norway (the
HUNT Study). Among 85100 eligible persons, 77310 (90.8%)
returned the questionnaire that was mailed with the invitation
(questionnaire 1), of whom 74977 (38274 women) participated in
the subsequent clinical examination. At this clinical examination,
standardised measurements of height, weight and blood pressure
were performed, and participants received a second questionnaire
that included items on physical activity, alcohol use, diabetes and
smoking. This second questionnaire was filled in at home and
returned in a prestamped envelope, but 6255 women (17%) did not
do so. Details of the description of the HUNT Study are provided
elsewhere (Holmen et al, 1991).
Among the 38274 women who participated, 1094 were excluded
because of prevalent cancer (of any site, except basal cell
carcinoma) and 419 were excluded because BMI could not be
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and were followed up for cancer incidence.
The unique 11-digit identity number of Norwegian citizens
enabled linkage of participants to endometrial cancer recorded at
the Cancer Registry of Norway. All women so diagnosed among
participants (International Classification of Diseases, 7th revision,
ICD-7, code 172) were identified based on mandatory reporting
from all pathological laboratories in Norway to the Cancer Registry.
Follow-up time was calculated as person-years from the date
of clinical examination until the date of cancer diagnosis
(except basal cell carcinoma), emigration, death or to the end of
follow-up at 31 December 2002, whichever occurred first. In
separate analyses among women before the age of 55 years, follow-up
was the time from the date of clinical examination until endometrial
cancer diagnosis or until censoring at the age of 55 years.
Body mass index was calculated as weight divided by height
squared (kgm
 2) and categorised as o20, 20–24, 25–29, 30–34,
35–39, and 40kgm
 2 and higher. At the clinical examination,
blood pressure X140/90mmHg was classified as hypertension.
Smoking status was coded as never, former, current or ‘missing’.
Alcohol drinking was categorised as 0, 1–4, X5 times during the
last 2 weeks, total abstainer or missing. Questions on recreational
physical activity (i.e., walking, skiing, swimming or other sports)
included frequency (five categories), average duration (four cate-
gories) and intensity (three categories). Marital status (married,
unmarried, widow and divorced/separated) and level of education
(o10, 10–12, 412 years or missing) were also recorded.
Statistical analysis
We estimated the age-adjusted relative risks (RRs) of BMI, diabetes
and smoking with 95% confidence intervals (CIs) by using the Cox
regression analysis. Thereafter, we mutually adjusted for each study
factor and also for alcohol use, physical activity and hypertension.
We used the SPSS statistical package, version 14.0, for the analysis.
This study was approved by the Regional Committee for Ethics
in Medical Research and the Norwegian Data Inspectorate.
RESULTS
We followed 36761 women for an average of 15.7 years (range
0–19 years). Mean age at baseline was 49 years (range 20–101 years),
and during follow-up, 222 endometrial cancers were diagnosed.
Among women with BMIo20kgm
 2, only 0.13% (4 out of 3067)
developed endometrial cancer compared to 3.66% (9 out of 246) of
those with BMIX40kgm
 2. Only 0.7% women (246) were in the
highest BMI category, but they represented 4.1% of those with
endometrial cancer. We found a strong and consistent increase in
risk with increasing BMI (P-trend o0.001) (Table 1). Compared to
women with BMI of 20–24kgm
 2, the age-adjusted RR for
BMIo20kgm
 2 was 0.51 (95% CI: 0.19–1.40), and with
BMIX40kgm
 2, it was 7.89 (95% CI: 3.90–15.94). Adjusting for
diabetes, smoking status, alcohol use, physical activity and
hypertension reduced the associations with BMI, but they
remained strong. The adjusted RRs were 6.36 (95% CI:
3.08–13.16) for BMIX40kgm
 2, 4.28 (95% CI: 2.58–7.09) for BMI
35–39kgm
 2 and 0.53 (95% CI: 0.19–1.47) for BMIo20kgm
 2,
respectively (Table 1).
Among women with diabetes at baseline, 1.88% women (19 out
of 1010) were diagnosed with endometrial cancer during follow-up
compared to 0.57% (203 out of 35751) among women without
diabetes. After multivariable adjustment, diabetes was associated
with a three-fold higher risk (RR 3.13, 95% CI: 1.92–5.11)
(Table 1).
There was an inverse association of current smoking with risk.
After multivariable adjustment, the negative association with
smoking was moderately reduced but remained strong (RR 0.55,
95% CI: 0.35–0.86); former smoking was not associated with risk
(RR 1.06, 95% CI: 0.71–1.61) (Table 1).
Because information on age at menopause was not available, we
conducted separate analyses before and after the age of 55 years.
Among the 22027 women who could be followed until the age of 55
years, 52 developed endometrial cancer, but multivariate analyses
revealed a significantly increased risk only for women with
BMIX35kgm
 2. The RRs were 6.10 (95% CI: 1.95–19.05)
for BMI 35–39kgm
 2 and 9.44 (95% CI: 2.01–44.38) for
BMIX40kgm
 2 (Table 2) as compared to the reference group
(BMI 20–24kgm
 2).
Among women older than 55 years, 170 cases were diagnosed
during follow-up. These showed a linear increase with increasing
BMI, and RRs were 6.07 (95% CI: 2.65–13.93) associated with
BMIX40kgm
 2 and 4.20 (95% CI: 2.37–7.47) with BMI
35–39kgm
 2 (Table 2).
Initially, marital status and educational level were included, but
since they were not associated with risk, they were not included in
the final analysis.
Table 1 BMI, diabetes and smoking, and RR of endometrial cancer in the study population of 36761 women in Norway
Variable No. of persons No. of cases Age-adjusted RR
a Multivariate RR
b 95% CI P for trend
BMI (kgm
 2)
o20 3067 4 0.51 0.53 0.19–1.47
X20–24 17966 64 1.0 1.0
X25–29 10830 90 1.83 1.74 1.25–2.43
X30–34 3680 32 1.88 1.66 1.06–2.59
X35–39 972 23 5.04 4.28 2.58–7.09
X40 246 9 7.89 6.36 3.08–13.16 o0.001
Diabetes
No 35751 203 1.0 1.0
Yes 1010 19 3.84 3.13 1.92–5.11 o0.001
Smoking
Never 16433 122 1.0 1.0
Former 4635 31 1.07 1.06 0.71–1.61
Current 9438 26 0.49 0.55 0.35–0.86
Missing 6255 43 1.14 1.05 0.56–1.97 0.09
BMI¼body mass index; CI¼confidence interval; RR¼relative risk.
aAdjusted for age in 10-year categories (o30, 30–39, 40–49, 50–59, 60–69 and X70 years).
bAdjusted for
age in 10-year categories (o30, 30–39, 40–49, 50–59, 60–69 and X70 years), physical activity (no, low, moderate, high and missing), hypertension (o140/90 and X140/
90mmHg) and alcohol consumption during the last 2 weeks (abstinent, never, 1–4 times, 45 times and missing) and each study factor.
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Among the 36761 women followed for 15.7 years, we found a strong
positive and linear association of BMI with endometrial cancer risk
in the study population as a whole. We found a six-fold increase in
risk among very obese women (X40kgm
 2) compared to those of
normal BMI (20–24kgm
 2), whereas those women with
BMIo20kgm
 2 had only half the risk. Women with diabetes had
three-fold higher risk compared to non-diabetic women, and we
found an inverse association with smoking at baseline.
A weakness of our study is the lack of control for reproductive
factors, such as parity, oral contraceptive use, hormone replace-
ment therapy (HRT) and possible changes in BMI during
follow-up. Generally, Norwegian women were restrictive in HRT
use in the 1980s, with an estimated less than 6% of postmeno-
pausal women using it in the late 1980s (Graff-Iversen et al, 1998).
Hormone replacement therapy use increased in the 1990s when
about 35% of postmenopausal women reported using it. However,
users of combined oestrogen–progesterone preparations, who
constituted 70% of all Norwegian users, have had no increase in
endometrial cancer risk (Bakken et al, 2004). Women who had
undergone hysterectomy could not be excluded in our study
because of the lack of such information. The hysterectomy rate due
to benign disease has been low in Norway, although it has
increased in recent years (Kalseth and Backe, 2002).
Even though the association between obesity and endometrial
cancer is ‘convincing’ (IARC, 2002), it is still not clear if this
displays a linear gradient. Besides a linear relation, with no
evidence for any threshold effect in the population as a whole, the
associations in our study were stronger than in most previous
studies (Furberg and Thune, 2003; Jonsson et al, 2003; Schouten
et al, 2006). The higher impact of BMI on risk may be because
previous studies did not address the effect of very high body mass
separately, while others did not adjust for potentially confounding
factors (Tretli and Magnus, 1990; Bjorge et al, 2007).
The association with diabetes is also stronger than that
previously reported (Goodman et al, 1997; Weiderpass et al,
1997; Shoff and Newcomb, 1998; Friberg et al, 2007). In line with
most studies (Austin et al, 1993; Brinton et al, 1993; Weiderpass
and Baron, 2001; Viswanathan et al, 2005), we found an inverse
association with smoking at baseline after controlling for potential
confounding by other factors.
The fact that obesity increases risk has been attributed to changes
in concentrations of endogenous hormones in obese women.
Oestrogens produced in adipose tissue have a direct mitogenic
effect on endometrial cells, and in obese women, this effect is
assumed not to be counterbalanced by progesterone because of
chronic anovulation and thereby much reduced progesterone
synthesis. It has even been argued that low progesterone, rather
than increased oestrogens, is the predominant determinant of
endometrial cancer in premenopausal women and that the increased
risk is only related to oestrogens when oestrogen concentrations are
comparatively low, as found in postmenopausal women.
Progesterone counterbalances oestrogen and diminishes oestro-
genic action in the endometrium. As obesity is related to
both anovulation and low progesterone, these mechanisms are
irrelevant in younger women with high BMI. In postmenopausal
women, oestrogens derived from peripheral adipose tissue are the
primary source of endogenous E2, and the rate of production is
related to the size of the adipose depots. It can be argued that only
in those women, with comparably low oestrogen concentration,
risk is directly related to circulating oestrogen. Our results may
support the hypothesis of different mechanisms in different age
groups leading to a threshold effect of BMI in younger
premenopausal women. However, data from this study population
are insufficient to draw a definite conclusion.
There are indeed several possible mechanisms related to body
mass that are identical in pre- and postmenopausal women. Firstly,
there is a weight-related increase in insulin and insulin-like growth
factor-I (IGF-I), both of which are endometrial growth factors
(Crave et al, 1995; Pasquali et al, 1997). Secondly, cytokines
produced in fat tissue (leptin and adiponectin) may play a direct
role in endometrial carcinogenesis (Petridou et al, 2002; Dal Maso
et al, 2004; Housa et al, 2006), as well as transcription factors that
can modulate both cellular lipid metabolism and tumorigenesis
(Roberts-Thomson, 2000; Fajas et al, 2001).
Apart from the effects of unopposed oestrogens, insulin and
associated growth factors have been identified as risk factors. We
found a positive association of diabetes with risk, also after
adjusting for potentially confounding factors. Several mechanisms
may operate in linking elevated insulin to endometrial
cancer development, including growth-enhancing properties of
insulin, increased levels of IGF-I receptors in the cancer tissue
(Talavera et al, 1990; Roy et al, 1999) and suppressed gene
expression of endometrial IGFBP-1, leading to increased biological
activity of IGF-I (Irwin et al, 1993; Ayabe et al, 1997).
The protective effect of smoking on risk cannot be entirely
attributed to lower body weight. Reversible processes are probably
involved, since the finding was restricted to current, but not former,
smokers. Smoking may slow down the decay of progesterone and
androgens (Sowers et al, 2001), and thereby reduce oestrogen-
mediated cellular proliferation and mutations in endometrial glands.
It also has a direct anti-oestrogenic effect, and there appears to be a
direct toxic effect on the ovaries (Matikainen et al, 2001).
Table 2 BMI and RR of endometrial cancer in women younger and older than 55 years of age
Age (years) BMI (kgm
 2) No. of persons No. of cases Age-adjusted RR
a Multivariate RR
b 95% CI P for trend
o55 o20 2515 3 0.7 0.75 0.23–2.50
X20–24 13030 25 1.0 1.0
X25–29 4851 15 1.56 1.49 0.78–2.87
X30–34 1206 3 1.27 1.24 0.37–4.20
X35–39 333 4 6.13 6.10 1.95–19.05
X40 92 2 10.18 9.44 2.01–44.38 0.007
X55 o20 1205 1 0.27 0.28 0.04–2.01
X20–24 10485 39 1.0 1.0
X25–29 8906 75 1.95 1.85 1.25–2.75
X30–34 3224 29 2.06 1.77 1.07–2.93
X35–39 868 19 5.04 4.20 2.37–7.47
X40 220 7 7.79 6.07 2.65–13.93 o0.001
BMI¼body mass index; CI¼confidence interval; RR¼relative risk.
aAdjusted for age in 10-year categories (o30, 30–39, 40–49, 50–59, 60–69 and X70 years).
bAdjusted for
age in 10-year categories (o30, 30–39, 40–49, 50–59, 60–69 and X70 years), diabetes (yes/no), smoking (never, former, current and missing), physical activity (no, low,
moderate, high and missing), hypertension (o140/90 and X140/90mmHg) and alcohol consumption during the last 2 weeks (abstinent, never, 1–4 times, 45 times and
missing).
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linear and strong positive association of BMI with risk implies that
even a slight increase in population body mass will lead to an
increase in endometrial cancer incidence. More detailed research is
indicated.
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